Tradestie Institutional Equity Comparison Engine

ALXO vs FDMT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ALXO Overall Edge

ALXO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ALX Oncology Holdings Inc. Common Stock (ALXO) driven by superior Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, ALXO trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, ALXO sits in BREAKDOWN (20th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ALXO N/M vs FDMT N/M Fwd P/E
Growth & Margin Winner ALXO
Op Margin 0.0% vs -222.7% ยท YoY -100.0% vs +4505.6%
Momentum & Technical Winner FDMT
1Y -22.5% vs +13.3% ยท 52W Pos 5% vs 47%
Options & Structure Winner ALXO
BREAKDOWN (20th %ile IV) vs BREAKDOWN (10th %ile IV)
ALXO NASDAQ
ALX Oncology Holdings Inc. Common Stock
Pharmaceutical Preparations
$0.95
-9.07% 1D
Market Cap $149.3M
1M Return -10.78%
1Y Return -22.48%
Forward P/E N/M
Unified AI Score
63.1 / 100 BUY
Tech 50.0 Fund 61.0 Flow 68.0 Mom 70.0
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ALXO -22.48% FDMT +13.33% Spread: +35.81 pp (FDMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ALXO Revenue FDMT Revenue ALXO Op. Margin FDMT Op. Margin Margin Edge
FY2018 $0M N/A -662.0% N/A ALXO
FY2019 $0M $10M -400.0% -729.4% ALXO
FY2020 $0M $10M -3694.0% -424.0% FDMT
FY2021 N/A $20M N/A -395.5% FDMT
FY2022 N/A $0M N/A -3516.5% FDMT
FY2023 N/A $20M N/A -544.6% FDMT
FY2024 N/A $0M N/A -507678.4% FDMT
FY2025 N/A $90M N/A -187.2% FDMT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ALXO (3) vs FDMT (5)
Institutional Metric ALXO FDMT Criterion Row Winner
Market Capitalization Scale $149.3M $669.3M Larger Scale FDMT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% +4505.6% Higher Growth FDMT
Operating Margin (TTM) Profitability 0.0% -222.7% Higher Margin ALXO
Net Profit Margin Profitability 0.0% -208.6% Higher Margin ALXO
Return on Equity (ROE) Capital Efficiency -80.7% -56.7% Higher ROE FDMT
52-Week Range Position Momentum 5% ($1โ€“$3) 47% ($7โ€“$17) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 1.46ฮฒ ยท 117% Vol 1.89ฮฒ ยท 90% Vol Lower Realized Risk FDMT
Unified Institutional Score Composite Signal 63.1 / 100 (BUY) 51.3 / 100 (HOLD) Higher Composite ALXO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ALXO vs FDMT Buy Guide
ALXO BREAKDOWN
93d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live ALXO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ALXO nor FDMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.